Study guide
12.1 Site Startup Operations
Certified Clinical Research Coordinator CCRC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Concepts and Research Design
1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics
2 Chapter 2: Ethical Principles and Guidelines
2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent
3 Chapter 3: IRB/IEC Oversight and Participant Safety
3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting
4 Chapter 4: Participant Rights and Ethics
4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials
5 Chapter 5: Product Development and Regulatory Framework
5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)
6 Chapter 6: Investigational Product Accountability
6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction
7 Chapter 7: Regulatory Submissions and Actions
7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development
8 Chapter 8: Clinical Trial Operations and GCP Principles
8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight
9 Chapter 9: Essential Documents and Site Qualification
9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)
10 Chapter 10: Protocol Deviations and Amendments
10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control
11 Chapter 11: Monitoring Visits and Audits
11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits
12 Chapter 12: Study and Site Management - Startup
12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation
13 Chapter 13: Enrollment and Recruitment
13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics
14 Chapter 14: Daily Trial Coordination
14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)
15 Chapter 15: Quality Improvement and Site Closeout
15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures
16 Chapter 16: Source Documentation and Case Report Forms
16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems
17 Chapter 17: Data Management and Queries
17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails
18 Chapter 18: Data Privacy and Records Retention
18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics
12.1 Site Startup Operations
Key Takeaways Explain This Topic AI
Site feasibility involves assessing the site's capability to enroll the required number of eligible subjects and conduct the protocol.
The Pre-Study Visit (PSV) or Site Selection Visit (SSV) is conducted by the sponsor to evaluate the site's facilities, staff, and interest.
Essential regulatory documents include the Form FDA 1572, PI and Sub-I CVs, Financial Disclosure Forms (FDFs), and medical licenses.
IRB/IEC approval must be obtained for the protocol, Investigator's Brochure (IB), Informed Consent Form (ICF), and any subject-facing materials before study initiation.
Last updated: October 2026
Overview of Site Startup
Site startup is one of the most resource-intensive and critical phases in the lifecycle of a clinical trial. It spans from the initial contact by a sponsor or Contract Research Organization (CRO) to the point where the site is fully activated and ready to screen its first subject. For a Clinical Research Coordinator (CRC), mastering startup operations is essential, as delays in this phase directly impact the overall timeline of the trial.
The startup phase typically involves several parallel tracks: site feasibility and selection, regulatory document collection, Institutional Review Board (IRB) or Independent Ethics Committee (IEC) submissions, and contract/budget negotiations.
Site Feasibility and Qualification
Before a site is selected, the sponsor must determine if the site has the appropriate patient population, facilities, and experienced staff to conduct the trial. This process begins with a Site Feasibility Questionnaire .
The Feasibility Questionnaire
The CRC often takes the lead in completing the feasibility questionnaire in collaboration with the Principal Investigator (PI). This document requests detailed information regarding:
Patient Population: Retrospective data on how many patients with the target indication the site sees per month, and a realistic estimate of how many could be enrolled.
Competing Trials: Whether the site is currently conducting other trials that target the same patient population, which could hinder enrollment.
Site Infrastructure: Availability of required equipment (e.g., -70°C freezers, centrifuges, specific imaging modalities like MRI or PET scanners).
Staffing: The experience level of the PI, sub-investigators, CRCs, and other key personnel.
Pre-Study Visit (PSV) / Site Selection Visit (SSV)
If the feasibility questionnaire indicates that the site is a good fit, the sponsor or CRO will schedule a Pre-Study Visit (PSV), also known as a Site Selection Visit (SSV). During this visit, a Clinical Research Associate (CRA) will:
Tour the facility to verify the infrastructure.
Meet with the PI to discuss the protocol and gauge their interest and commitment.
Review the proposed recruitment strategy.
Assess the experience and availability of the research staff.
Pro-Tip for CRCs: Prepare for the PSV by reserving a quiet space for the CRA, ensuring the PI is available for their scheduled time, and having requested documentation (like equipment calibration logs) readily available.
Essential Regulatory Documents
Once a site is selected, the regulatory startup phase begins. The CRC or a dedicated Regulatory Coordinator must compile the essential document packet. These documents are required by Good Clinical Practice (GCP) and regulatory agencies (like the FDA) before investigational product (IP) can be shipped to the site.
Key Regulatory Documents
Document Purpose and Key Details
Form FDA 1572 (Statement of Investigator) A legally binding document where the PI agrees to comply with FDA regulations. It lists the PI, sub-investigators, study location, local lab, and the IRB.
Curriculum Vitae (CV) Required for the PI and all sub-investigators to prove their qualifications. Must be current, as the sponsor requires.
Medical Licenses Proof of active medical licenses for all physicians listed on the 1572.
Financial Disclosure Form (FDF) Investigators must disclose any significant financial interests in the sponsor company to identify potential conflicts of interest.
Laboratory Documents CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists) certificates, plus the lab's normal reference ranges.
Protocol Signature Page Signed by the PI to acknowledge receipt and agreement to follow the protocol.
Gathering these documents promptly is a primary responsibility. A common bottleneck is obtaining signatures from busy physicians, so setting up an efficient e-signature workflow or dedicated signing times can expedite the process.
IRB/IEC Submissions
No clinical trial procedures can begin until the study has been reviewed and approved by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC). The IRB's primary mandate is to protect the rights, safety, and well-being of human subjects.
Central vs. Local IRBs
Sites may use a Local IRB (typically an internal committee at a university or large hospital system) or a Central IRB (an independent, commercial board used by multiple sites in a multicenter trial).
Central IRBs: Often process submissions faster. The sponsor usually submits the main protocol and investigator's brochure, while the site submits site-specific details (like the PI's qualifications and site-specific informed consent language).
Local IRBs: May require more extensive internal routing and approvals (e.g., scientific review committees, radiation safety committees) before the IRB will even review the submission.
The Initial Submission Packet
The CRC typically prepares the initial IRB submission, which must include:
The Clinical Trial Protocol (and any amendments).
The Investigator's Brochure (IB) (which contains all pre-clinical and clinical data on the investigational product).
The Informed Consent Form (ICF) . The sponsor provides a master ICF, but the site must add local language regarding subject injury, compensation, and local contact information.
Subject-Facing Materials: Any recruitment flyers, radio scripts, questionnaires, or diaries the subject will see.
PI Qualifications: The PI's CV and medical license.
Managing IRB Stipulations
Rarely does an IRB approve a study on the first pass without any questions. They will often issue stipulations or requests for modifications. The CRC must review these promptly with the PI, make the necessary changes to the ICF or other documents, and submit the responses. Time is of the essence; a delay in responding to the IRB directly delays site activation.
The Road to Site Activation
Site activation, or the "green light," is the culmination of all startup activities. It means the site has full IRB approval, a fully executed clinical trial agreement (CTA) and budget, and all essential regulatory documents have been approved by the sponsor. Only after receiving this formal notification can the site schedule the Site Initiation Visit (SIV) and eventually begin screening subjects. By managing startup operations proactively, the CRC ensures the site contributes to the trial's success from day one.